keyword
MENU ▼
Read by QxMD icon Read
search

Oxaliplatin

keyword
https://www.readbyqxmd.com/read/28724889/aptamer-mediated-survivin-rnai-enables-5-fluorouracil-to-eliminate-colorectal-cancer-stem-cells
#1
Hadi AlShamaileh, Tao Wang, Dongxi Xiang, Wang Yin, Phuong Ha-Lien Tran, Roberto A Barrero, Pei-Zhuo Zhang, Yong Li, Lingxue Kong, Ke Liu, Shu-Feng Zhou, Yingchun Hou, Sarah Shigdar, Wei Duan
The development of chemoresistance and inability in elimination of cancer stem cells are among the key limitations of cancer chemotherapy. Novel molecular therapeutic strategies able to overcome such limitations are urgently needed for future effective management of cancer. In this report, we show that EpCAM-aptamer-guided survivin RNAi effectively downregulated survivin both in colorectal cancer cells in vitro and in a mouse xenograft model for colorectal cancer. When combined with the conventional chemotherapeutic agents, the aptamer-guided survivin RNAi was able to enhance the sensitivity towards 5-FU or oxaliplatin in colorectal cancer stem cells, increase apoptosis, inhibit tumour growth and improve the overall survival of mice bearing xenograft colorectal cancer...
July 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28723668/a-rare-case-of-esophageal-metastasis-from-pancreatic-ductal-adenocarcinoma-a-case-report-and-literature-review
#2
Lauren M Rosati, Megan N Kummerlowe, Justin Poling, Amy Hacker-Prietz, Amol K Narang, Eun J Shin, Dung T Le, Elliot K Fishman, Ralph H Hruban, Stephen C Yang, Matthew J Weiss, Joseph M Herman
PURPOSE: We report a very unique case of an esophageal metastasis from a pancreatic ductal adenocarcinoma (PDAC) primary. METHODS: After obtaining consent from the patient, all relevant records of the case were obtained and retrospectively reviewed. RESULTS: At presentation, the patient was diagnosed with synchronous pancreatic and esophageal cancer. He received six months of neoadjuvant therapy including FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) and stereotactic body radiation therapy (SBRT) to the pancreatic tumor followed by a combined pancreaticoduodenectomy and Ivor Lewis esophagectomy...
June 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28714953/gut-microbiota-is-critical-for-the-induction-of-chemotherapy-induced-pain
#3
Shiqian Shen, Grewo Lim, Zerong You, Weihua Ding, Peigen Huang, Chongzhao Ran, Jason Doheny, Peter Caravan, Samuel Tate, Kun Hu, Hyangin Kim, Michael McCabe, Bo Huang, Zhongcong Xie, Douglas Kwon, Lucy Chen, Jianren Mao
Chemotherapy-induced pain is a dose-limiting condition that affects 30% of patients undergoing chemotherapy. We found that gut microbiota promotes the development of chemotherapy-induced mechanical hyperalgesia. Oxaliplatin-induced mechanical hyperalgesia was reduced in germ-free mice and in mice pretreated with antibiotics. Restoring the microbiota of germ-free mice abrogated this protection. These effects appear to be mediated, in part, by TLR4 expressed on hematopoietic cells, including macrophages.
July 17, 2017: Nature Neuroscience
https://www.readbyqxmd.com/read/28714912/urinary-excretion-of-tetrodotoxin-modeled-in-a-porcine-renal-proximal-tubule-epithelial-cell-line-llc-pk%C3%A2
#4
Takuya Matsumoto, Yui Ishizaki, Keika Mochizuki, Mitsuru Aoyagi, Yoshiharu Mitoma, Shoichiro Ishizaki, Yuji Nagashima
This study examined the urinary excretion of tetrodotoxin (TTX) modeled in a porcine renal proximal tubule epithelial cell line, LLC-PK₁. Time course profiles of TTX excretion and reabsorption across the cell monolayers at 37 °C showed that the amount of TTX transported increased linearly for 60 min. However, at 4 °C, the amount of TTX transported was approximately 20% of the value at 37 °C. These results indicate that TTX transport is both a transcellular and carrier-mediated process. Using a transport inhibition assay in which cell monolayers were incubated with 50 µM TTX and 5 mM of a transport inhibitor at 37 °C for 30 min, urinary excretion was significantly reduced by probenecid, tetraethylammonium (TEA), l-carnitine, and cimetidine, slightly reduced by p-aminohippuric acid (PAH), and unaffected by 1-methyl-4-phenylpyridinium (MPP+), oxaliplatin, and cefalexin...
July 17, 2017: Marine Drugs
https://www.readbyqxmd.com/read/28714378/utilization-of-capecitabine-plus-oxaliplatin-and-5-fluorouracil-folinic-acid-plus-oxaliplatin-in-the-adjuvant-treatment-of-stage-iib-and-stage-iii-colon-cancer-a-multi-centre-retrospective-chart-review-study
#5
Aaron Sha, Shirin Abadi, Sharlene Gill
Purpose First, to assess drug utilization rates of capecitabine plus oxaliplatin (CAPOX) versus 5-fluorouracil plus oxaliplatin (mFOLFOX6) regimens in the treatment of stage IIB and stage III colon cancer. Second, to assess patient characteristics used to select CAPOX versus FOLFOX therapy, dose-limiting toxicities, dose intensities and treatment completion rates. Methods Patients with resected stage IIB or stage III colon cancer from five British Columbia Cancer Agency centres treated with CAPOX or mFOLFOX6 were selected for the analysis...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28714373/targeting-mir-21-decreases-expression-of-multi-drug-resistant-genes-and-promotes-chemosensitivity-of-renal-carcinoma
#6
Kelly Gaudelot, Jean-Baptiste Gibier, Nicolas Pottier, Brigitte Hémon, Isabelle Van Seuningen, François Glowacki, Xavier Leroy, Christelle Cauffiez, Viviane Gnemmi, Sébastien Aubert, Michaël Perrais
Renal cell carcinoma, the most common neoplasm of adult kidney, accounts for about 3% of adult malignancies and is usually highly resistant to conventional therapy. MicroRNAs are a class of small non-coding RNAs, which have been previously shown to promote malignant initiation and progression. In this study, we focused our attention on miR-21, a well described oncomiR commonly upregulated in cancer. Using a cohort of 99 primary renal cell carcinoma samples, we showed that miR-21 expression in cancer tissues was higher than in adjacent non-tumor tissues whereas no significant difference was observed with stages, grades, and metastatic outcome...
July 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28712693/diagnostic-performance-of-contrast-enhanced-ct-scan-in-sinusoidal-obstruction-syndrome-induced-by-chemotherapy-of-colorectal-liver-metastases-radio-pathological-correlation
#7
Sophie Cayet, Jeremy Pasco, Fanny Dujardin, Marie Besson, Isabelle Orain, Anne De Muret, Elodie Miquelestorena-Standley, Julien Thiery, Thibaud Genet, Anne-Gwenn Le Bayon
PURPOSE: Sinusoidal obstruction syndrome (SOS) is a likely side effect of colorectal liver metastases (CRLM) chemotherapy. This study aimed to assess computed tomography scan (CT-scan) performance for SOS diagnosis for patients receiving neoadjuvant chemotherapy (NC) prior to CRLM surgery, comparing obtained results with pathological gold standard. METHODS: Preoperative CT-scans of 67 patients who had received a NC prior to liver resection for CRLM from 2011 to 2016 were retrospectively analysed...
July 3, 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28712098/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-1-biologic-therapies-targeting-the-epidermal-growth-factor-receptor-and-vascular-endothelial-growth-factor
#8
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
The survival of patients with metastatic colorectal cancer has improved dramatically in recent years, with overall survival exceeding 3 years in large randomized clinical trials. There are now several treatment options for patients with metastatic colorectal cancer. In addition to chemotherapy backbones utilizing fluoropyrimidine, oxaliplatin, and irinotecan combinations, biologic agents that target specific oncogenic pathways have contributed to the improved survival observed in this patient population. This class of medications includes epidermal growth factor receptor (EGFR)-targeted drugs (cetuximab and panitumumab) and vascular endothelial growth factor (VEGF)-targeted therapies (bevacizumab, ramucirumab, ziv-aflibercept, and regorafenib)...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28711577/a-randomised-phase-ii-study-of-continuous-versus-stop-and-go-s-1-plus-oxaliplatin-following-disease-stabilisation-in-first-line-chemotherapy-in-patients-with-metastatic-gastric-cancer
#9
Sook Ryun Park, Mi-Jung Kim, Byung-Ho Nam, Chan Gyoo Kim, Jong Yeul Lee, Soo-Jeong Cho, Sun-Young Kong, Young-Iee Park
OBJECTIVES: We compared continuous versus stop-and-go chemotherapy after disease stabilisation with induction chemotherapy in the first-line treatment of metastatic gastric cancer (MGC). METHODS: MGC patients who achieved disease control after 6 cycles of S-1/oxaliplatin (SOX) were randomised to receive either continuous SOX until progression (continuous arm) or to have a chemotherapy-free interval followed by SOX reintroduction at progression (stop-and-go arm)...
July 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28711275/chemotherapy-induced-stroke-mimic-5-fluorouracil-encephalopathy-fulfilling-criteria-for-tissue-plasminogen-activator-therapy
#10
May Thuy Nguyen, Robyn Stoianovici, Luigi Brunetti
Stroke mimics, especially those involving chemotherapy related neurotoxicity, can confound the clinical diagnosis of acute stroke. Here we describe the case of a 63year-old male with a recent history of stage IIIC colon cancer who presented with confusion on the second day of modified FOLFOX6 (5-fluorouracil/oxaliplatin) chemotherapy and subsequently received alteplase, tissue plasminogen activator therapy (tPA), for presumed ischemic stroke. Magnetic resonance imaging scans after tPA administration did not reveal evidence of an infarction and the patients' neurological symptoms resolved completely after discontinuation of 5-fluorouracil (5-FU)...
July 6, 2017: American Journal of Emergency Medicine
https://www.readbyqxmd.com/read/28708932/tandem-repeat-variation-near-the-hic1-hypermethylated-in-cancer-1-promoter-predicts-outcome-of-oxaliplatin-based-chemotherapy-in-patients-with-metastatic-colorectal-cancer
#11
Satoshi Okazaki, Marta Schirripa, Fotios Loupakis, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Martin D Berger, Yuji Miyamoto, Mitsukuni Suenaga, Syma Iqubal, Afsaneh Barzi, Chiara Cremolini, Alfredo Falcone, Francesca Battaglin, Lisa Salvatore, Beatrice Borelli, Timothy G Helentjaris, Heinz-Josef Lenz
BACKGROUND: The hypermethylated in cancer 1/sirtuin 1 (HIC1/SIRT1) axis plays an important role in regulating the nucleotide excision repair pathway, which is the main oxaliplatin-induced damage-repair system. On the basis of prior evidence that the variable number of tandem repeat (VNTR) sequence located near the promoter lesion of HIC1 is associated with HIC1 gene expression, the authors tested the hypothesis that this VNTR is associated with clinical outcome in patients with metastatic colorectal cancer who receive oxaliplatin-based chemotherapy...
July 14, 2017: Cancer
https://www.readbyqxmd.com/read/28708138/blocking-endothelin-1-receptor-%C3%AE-catenin-circuit-sensitizes-to-chemotherapy-in-colorectal-cancer
#12
Roberta Cianfrocca, Laura Rosanò, Piera Tocci, Rosanna Sestito, Valentina Caprara, Valeriana Di Castro, Ruggero De Maria, Anna Bagnato
The limited clinical response to conventional chemotherapeutics observed in colorectal cancer (CRC) may be related to the connections between the hyperactivated β-catenin signaling and other pathways in CRC stem-like cells (CRC-SC). Here, we show the mechanistic link between the endothelin-1 (ET-1)/ET-1 receptor (ET-1R) signaling and β-catenin pathway through the specific interaction with the signal transducer β-arrestin1 (β-arr1), which initiates signaling cascades as part of the signaling complex. Using a panel of patient-derived CRC-SC, we show that these cells secrete ET-1 and express ETAR and β-arr1, and that the activation of ETAR/β-arr1 axis promotes the cross-talk with β-catenin signaling to sustain stemness, epithelial-to-mesenchymal transition (EMT) phenotype and response to chemotherapy...
July 14, 2017: Cell Death and Differentiation
https://www.readbyqxmd.com/read/28706257/efficacy-and-safety-of-taxane-based-systemic-chemotherapy-of-advanced-gastric-cancer-a-systematic-review-and-meta-analysis
#13
Jinxin Shi, Peng Gao, Yongxi Song, Xiaowan Chen, Yuan Li, Changwang Zhang, Hongchi Wang, Zhenning Wang
Taxanes are chemotherapeutic agents commonly used to treat several cancers. However, the effects of taxanes on advanced gastric cancer (AGC) are still not clear, especially when used as a first-line treatment. This systematic review and meta-analysis aims to investigate the efficacy and safety of taxanes as a first-line treatment of AGC. The quality of our included studies was assessed using the Cochrane risk of bias tool for RCTs and NOS scale for nRCTs, and the data of the included studies was of satisfactory quality to analyze...
July 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28705789/treatment-of-peritoneal-dissemination-in-stomach-cancer-patients-with-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec-rationale-and-design-of-the-periscope-study
#14
Rosa T van der Kaaij, Hidde Jw Braam, Henk Boot, Maartje Los, Annemieke Cats, Cecile Grootscholten, Jan Hm Schellens, Arend Gj Aalbers, Alwin Dr Huitema, Catherijne Aj Knibbe, Djamila Boerma, Marinus J Wiezer, Bert van Ramshorst, Johanna W van Sandick
BACKGROUND: Patients with gastric cancer and peritoneal carcinomatosis have a very poor prognosis; median survival is 3 to 4 months. Palliative systemic chemotherapy is currently the only treatment available in the Netherlands. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has an established role in the treatment of peritoneal carcinomatosis originating from colorectal cancer, appendiceal cancer, and pseudomyxoma peritonei; its role in gastric cancer is uncertain. Currently, there is no consensus on the choice of chemotherapeutic agents used in HIPEC for gastric cancer...
July 13, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28705006/best-practices-for-the-treatment-of-metastatic-pancreatic-adenocarcinoma-the-therapeutic-landscape-in-2017
#15
Pelin Cinar, Andrew H Ko
The vast majority of patients diagnosed with pancreatic adenocarcinoma have inoperable, most commonly metastatic, disease at the time of initial presentation, at which point systemic therapy becomes the mainstay of treatment. Although survival rates remain very poor in this clinical setting, patients currently have a greater number of therapeutic options available to them than ever before, and consequently individuals are more frequently able to be sequenced through multiple lines of treatment. In this review, we will provide an overview of the current treatment landscape for metastatic pancreatic cancer in 2017, focusing on best practices and the various factors that should be considered in selecting the most appropriate regimen for a given individual...
June 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28703890/targeted-therapies-in-pancreatic-cancer-promises-and-failures
#16
Matineh Barati Bagherabad, Fahimeh Afzaljavan, Soodabeh ShahidSales, Seyed Mahdi Hassanian, Amir Avan
Pancreatic ductal adenocarcinoma (PDAC) is an incidence rate nearly equal to its mortality rate. The poor prognosis of the disease can be explained by the absence of effective biomarkers for screening and early detection, together with the aggressive behavior and resistance to the currently available chemotherapy. The therapeutic failure can also be attributed to the inter-/intra- tumor genetic heterogeneity and the abundance of tumor stroma that occupies the majority of the tumor mass. Gemcitabine is used in the treatment of PDAC, however, the response rate is less than 12%...
July 13, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/28701590/new-perspectives-of-cobalt-tris-bipyridine-system-anti-cancer-effect-and-its-collateral-sensitivity-towards-multidrug-resistant-mdr-cancers
#17
Betty Yuen Kwan Law, Yuan Q Qu, Simon Wing Fai Mok, Hauwei Liu, Zeng Wu, Yu Han, Flora Gordillo-Martinez, Wai-Kit Chan, Keith M Wong, Vincent Kam Wai Wong
Platinating compounds including cisplatin, carboplatin, and oxaliplatin are common chemotherapeutic agents, however, patients developed resistance to these clinical agents after initial therapeutic treatments. Therefore, different approaches have been applied to identify novel therapeutic agents, molecular mechanisms, and targets for overcoming drug resistance. In this study, we have identified a panel of cobalt complexes that were able to specifically induce collateral sensitivity in taxol-resistant and p53-deficient cancer cells...
July 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/28696176/interstitial-lung-disease-following-folfox-folfiri-and-bevacizumab-therapy-associated-with-leucovorin-a-case-report
#18
Satoru Mitsuboshi, Hiromi Kozakai, Hitoshi Yamada, Kazuhiko Nagai, Tomoyasu Furukawa, Kikuo Aizawa
Chemotherapy-induced interstitial lung disease in colorectal cancer patients is rare but represents a life-threatening adverse reaction. We report here a case of interstitial lung disease following chemotherapy for metastatic colorectal cancer and the interesting results of the drug-induced lymphocyte stimulation test and leukocyte migration test. After chemotherapy with oxaliplatin plus infusional 5-fluorouracil and leucovorin (FOLFOX) plus bevacizumab followed by irinotecan plus infusional 5-fluorouracil and leucovorin (FOLFIRI), the patient was hospitalized with fever and chills...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28695397/effect-of-ninjin-yoeito-and-ginseng-extracts-on-oxaliplatin-induced-neuropathies-in-mice
#19
Toshiaki Suzuki, Ayano Yamamoto, Masahiro Ohsawa, Yoshiharu Motoo, Hajime Mizukami, Toshiaki Makino
Oxaliplatin (L-OHP) is a platinum-based anticancer agent used to treat various types of cancer. It frequently causes acute and chronic peripheral neuropathies, such as cold allodynia and mechanical hyperalgesia. Ninjin'yoeito (NYT) is a formula used in traditional Japanese Kampo medicine to improve recovery from diseases and other medical disorders. We previously reported that treatment with a boiling-water extract of NYT prevented L-OHP-induced damage to neurite-like outgrowths from differentiated PC12 cells...
July 10, 2017: Journal of Natural Medicines
https://www.readbyqxmd.com/read/28695301/optimal-use-of-anti-egfr-monoclonal-antibodies-for-patients-with-advanced-colorectal-cancer-a-meta-analysis
#20
REVIEW
E J van Helden, C W Menke-van der Houven van Oordt, M W Heymans, J C F Ket, R van den Oord, H M W Verheul
This meta-analysis was performed to determine the optimal use of anti-EGFR mAb in the treatment of metastasized colorectal cancer (mCRC). Seventeen randomized clinical trials were included, all evaluating the added value of anti-EGFR mAb to standard treatment line in patients with KRAS wild-type mCRC. Hazard and odds ratios were pooled using a random effect model, weighted according to cohort size. Pooled data of six first- and two second-line studies demonstrated a significantly improved ORR (OR 1.62, CI 1...
July 10, 2017: Cancer Metastasis Reviews
keyword
keyword
73953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"